Omega Therapeutics (NASDAQ:OMGA) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Omega Therapeutics (NASDAQ:OMGA) in a research report report published on Tuesday morning, Benzinga reports. The brokerage currently has a $12.00 price objective on the stock.

Other research analysts also recently issued research reports about the stock. Piper Sandler reaffirmed an overweight rating and issued a $9.00 price target (down previously from $10.00) on shares of Omega Therapeutics in a research note on Wednesday, April 3rd. Wedbush reaffirmed an outperform rating and issued a $12.00 price target on shares of Omega Therapeutics in a research note on Thursday, January 4th. Finally, Chardan Capital reduced their price target on shares of Omega Therapeutics from $12.00 to $7.00 and set a buy rating on the stock in a research note on Monday, April 1st.

Omega Therapeutics Trading Down 2.6 %

Shares of OMGA opened at $2.23 on Tuesday. Omega Therapeutics has a twelve month low of $1.30 and a twelve month high of $10.09. The company has a market cap of $122.98 million, a P/E ratio of -1.23 and a beta of 1.83. The company has a current ratio of 3.35, a quick ratio of 3.35 and a debt-to-equity ratio of 0.26. The company’s fifty day simple moving average is $3.29 and its 200-day simple moving average is $2.96.

Omega Therapeutics (NASDAQ:OMGA) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. The company had revenue of $0.99 million for the quarter, compared to the consensus estimate of $0.93 million. Omega Therapeutics had a negative net margin of 3,147.92% and a negative return on equity of 110.41%. As a group, analysts expect that Omega Therapeutics will post -1.37 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Etfidea LLC bought a new position in Omega Therapeutics during the 4th quarter worth about $39,000. Murphy Pohlad Asset Management LLC bought a new position in Omega Therapeutics during the 4th quarter worth about $50,000. Finally, 683 Capital Management LLC grew its holdings in Omega Therapeutics by 7.0% during the 3rd quarter. 683 Capital Management LLC now owns 508,242 shares of the company’s stock worth $1,093,000 after acquiring an additional 33,242 shares in the last quarter. 97.47% of the stock is currently owned by institutional investors.

Omega Therapeutics Company Profile

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.